1. The drug for infants, including a source of protein, a source of fat, a source of carbohydrates and B. longum AH1206. ! 2. The preparation for infants according to claim 1, characterized in that said preparation for infants includes B. longum AH1206 in an amount of from about 1 · 10 4 CFU to about 1 · 10 10 CFU per gram of preparation for infants. ! 3. The drug for infants according to claim 1, characterized in that B. longum AH1206 is viable. ! 4. The drug for infants according to claim 1, characterized in that B. longum AH1206 includes non-living bacteria. ! 5. The preparation for infants according to claim 1, including also an additional probiotic. ! 6. The drug for infants according to claim 5, characterized in that the additional probiotic includes LGG. ! 7. The drug for infants according to claim 1, which also includes a prebiotic. ! 8. The preparation for infants according to claim 7, characterized in that said prebiotic is selected from the group consisting of lactulose, gluco-oligosaccharide, inulin, polydextrose, galacto-oligosaccharide, fructo-oligosaccharide, isomalto-oligosaccharide, soy oligosaccharides, l -oligosaccharide and gentio-oligosaccharide. ! 9. The preparation for infants according to claim 1, also comprising at least one LCPUFA. ! 10. The preparation for infants according to claim 1, also including ARA and DHA. ! 11. Nutrient formula for children, including a protein source, a source of fat, a source of carbohydrates and B. longum AH1206. ! 12. A method of reducing or preventing inflammation in an infant or child, comprising administering B. longum AH1206 to an infant or child. ! 13. The method according to p. 12, characterized in that the said reduction or prevention of inflammation weakens the allergy. ! 14. The method according to p. 12, characterized in that said reduction or prevention of inflammation weakens asthma. ! 15. The method according to item 12, wherein1. Препарат для младенцев, включающий источник белка, источник жира, ис
